Introduction: Khorana score (KS) stratifies patients into low, intermediate, and high risk
groups for venous thromboembolism (VTE). We examined the generalizability of the KS to …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

BACKGROUND: Venous thromboembolism is a well-known complication of malignancy.
The Khorana Risk Score (KRS) utilizes the type of cancer, blood counts, and body mass …

Introduction: Although venous thromboembolism (VTE) is a well-known complication of
cancer, predicting and mitigating the risks associated with VTE related to cancer remain a …

Background The Khorana risk score (KRS) for prognosis of venous thromboembolism (VTE)
has been rarely explored in Hispanic populations. Objective To determine the value of the …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Background: Guidelines suggest the use of the Khorana score to select patients with solid
cancer receiving chemotherapy for thromboprophylaxis to prevent venous thromboembolism …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Abstract Background Although the Khorana venous thromboembolism (VTE) risk score
(KRS) is well recognized as a simple VTE risk assessment method in patients with cancer …

Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …